7 ms·
"Rights to the London treatment were sold to the biotech company Cellectis, and the treatment is now being further developed by the drug companies Servier and P
by CodeSheikh 10y ago
"Rights to the London treatment were sold to the biotech company Cellectis, and the treatment is now being further developed by the drug companies Servier and Pfizer."
And that's when it will get sunk into an abyss of bureaucratic processes and this treatment probably won't see sunlight for another ten years.
- tormeh 10y agoIn fairness, that is mostly the fault of the world's various regulatory agencies. I mean, I understand that it's easy, when asked "How many people should die yearly of insufficiently tested medicine?" to answer "zero!", but that's kind of how medicine became so stale.